{"id":164249,"date":"2026-11-22T02:50:31","date_gmt":"2026-11-22T02:50:31","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/164249\/"},"modified":"2026-11-22T02:50:31","modified_gmt":"2026-11-22T02:50:31","slug":"roche-hanmi-akeso-a-congressmans-concerns-fierce-pharma-asia","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/164249\/","title":{"rendered":"Roche-Hanmi, Akeso, a congressman&#8217;s concerns\u2014Fierce Pharma Asia"},"content":{"rendered":"<p>With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. Akeso&#8217;s CEO countered concerns over shrinking lung cancer data for ivonescimab as the PD-1xVEGF drug delivered its first phase 3 win outside lung cancer. A U.S. congressman says China is &#8220;beating us on our ground game&#8221; in biotech. And more.<\/p>\n<p>1. <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/roche-pens-25b-pact-hanmis-clinical-stage-obesity-drug-targeting-less-used-mechanism\" rel=\"nofollow noopener\" target=\"_blank\">Roche pens $2.5B pact for Hanmi\u2019s clinical-stage obesity drug targeting less-explored mechanism<\/a><\/p>\n<p>Roche is paying $190 million for a clinical-stage UCN2 analog from Korea\u2019s Hanmi. For up to $2.3 billion in additional milestone payments, Roche is betting the candidate, coded HM17321, could promote weight loss while preserving lean body mass. Besides obesity, Roche plans to explore the drug in other associated cardiometabolic conditions.<\/p>\n<p>2. <a href=\"https:\/\/www.fiercepharma.com\/pharma\/akeso-ceo-looks-beyond-lung-cancer-phase-3-biliary-tract-win-counters-ivonescimab-debate\" rel=\"nofollow noopener\" target=\"_blank\">Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate<\/a><\/p>\n<p>Akeso\u2019s ivonescimab posted its first phase 3 win outside lung cancer by delivering an overall survival benefit against AstraZeneca\u2019s Imfinzi in biliary tract cancer. Meanwhile, CEO Michelle Xia, Ph.D., finds herself defending weaker data from an exploratory longer-term analysis of the Harmoni-6 study in first-line squamous non-small cell lung cancer, as investors worry about its partner Summit Therapeutics\u2019 global Harmoni-3 readout.\u00a0\u00a0<\/p>\n<p>3. <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/texas-congressman-tells-fierce-why-chinese-biotechs-are-beating-us-our-ground-game\" rel=\"nofollow noopener\" target=\"_blank\">Why a Texas congressman believes Chinese biotechs are &#8216;beating us on our ground game&#8217;<\/a><\/p>\n<p>\u201cThe United States has been too focused on measuring the outcomes of strategic scenarios with China and not paid enough attention to the input,\u201d\u00a0Rep. Nathaniel Moran, R-Texas, a member of the House Select Committee on China, told Fierce. \u201cWe talk about the growing trials that are happening in China,&#8221; he continued. &#8220;What we forget to focus on is that they are beating us on our ground game.\u201d<\/p>\n<p>4. <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/founded-metsera-backers-sentivera-emerges-15b-inflammatory-disease-deal\" rel=\"nofollow noopener\" target=\"_blank\">Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal<\/a><\/p>\n<p>After selling Metsera to Pfizer, Arch Venture Partners and Population Health Partners have formed a new biotech, Sentivera, which emerged with a $40 million upfront deal with China\u2019s Haisco Pharmaceutical. The target is an inflammatory disease drug candidate that recently received clearance to enter clinical development in China.<\/p>\n<p>5. <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/china-moving-follower-frontrunner-pharma-hansoh\" rel=\"nofollow noopener\" target=\"_blank\">Hansoh heralds China\u2019s move from \u2018follower\u2019 to \u2018frontrunner\u2019 in biopharma race<\/a><\/p>\n<p>Hansoh Pharma, which has partnered with the likes of GSK, Roche and Regeneron, said China\u2019s biotech industry is \u201cfully transitioning from the \u2018follower\u2019 phase to the \u2018frontrunner\u2019 phase,\u201d according to its half-year results announcement. The company cited evidence that China now accounts for 30% of investigational medicines.\u00a0<\/p>\n<p>6. <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/sk-biopharma-pens-795m-deal-usher-biohavens-epilepsy-therapy-towards-fda\" rel=\"nofollow noopener\" target=\"_blank\">SK Biopharma pens $795M deal to usher Biohaven\u2019s epilepsy therapy towards hoped-for 2029 launch<\/a><\/p>\n<p>SK Biopharmaceuticals agreed to pay $350 million up front for Biohaven\u2019s Kv7 ion channel platform, led by opakalim, which is in a phase 2\/3 trial of patients with focal epilepsy. The Korean pharma hopes to leverage its experience with the epilepsy med Xcopri to speed the development and commercial rollout of opakalim.\u00a0<\/p>\n<p>Other News of Note:<\/p>\n<p>7. <a href=\"https:\/\/www.fiercepharma.com\/marketing\/daiichi-sankyo-promotes-ken-keller-lead-new-commercialization-unit\" rel=\"nofollow noopener\" target=\"_blank\">Daiichi Sankyo promotes Ken Keller to lead new commercialization unit<\/a><\/p>\n<p>8. <a href=\"https:\/\/www.fiercepharma.com\/pharma\/fierce-pharma-regulatory-tracker-2026-h2\" rel=\"nofollow noopener\" target=\"_blank\">GSK nabs first-of-its-kind hep B nod in Japan<\/a> (Regulatory tracker)<\/p>\n<p>9. <a href=\"https:\/\/www.bioraypharm.com\/index.php?m=content&amp;a=index&amp;classid=40&amp;id=217\" rel=\"nofollow noopener\" target=\"_blank\">BioRay Pharma CEO Wang Haibin passes away<\/a> (Obituary, Chinese)<\/p>\n","protected":false},"excerpt":{"rendered":"With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. Akeso&#8217;s CEO&hellip;\n","protected":false},"author":2,"featured_media":164250,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[67251,190,351,10374,76048,44259,41939,41991,76047,58395,41515,2536,134,59275],"class_list":["post-164249","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-akeso","tag-asia","tag-china","tag-daiichi-sankyo","tag-drug-approvals","tag-fierce-pharma-asia","tag-fierce-pharma-homepage","tag-gsk","tag-haisco-pharmaceutical-group","tag-hanmi-pharmaceutical","tag-licensing-deals","tag-pharma","tag-roche","tag-sk-biopharmaceuticals"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117657824665018817","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/164249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=164249"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/164249\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/164250"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=164249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=164249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=164249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}